Compare ZTS & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTS | KVUE |
|---|---|---|
| Founded | 1952 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5B | 36.9B |
| IPO Year | 2012 | 2023 |
| Metric | ZTS | KVUE |
|---|---|---|
| Price | $75.50 | $18.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $154.18 | $19.45 |
| AVG Volume (30 Days) | 4.8M | ★ 17.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | 1.86% | ★ 4.82% |
| EPS Growth | 10.05 | ★ 40.74 |
| EPS | ★ 3.08 | 0.48 |
| Revenue | $9,467,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $5.63 | $4.85 |
| Revenue Next Year | $4.77 | $2.63 |
| P/E Ratio | ★ $24.82 | $39.60 |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $71.00 | $14.02 |
| 52 Week High | $149.75 | $20.13 |
| Indicator | ZTS | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 48.58 |
| Support Level | $73.02 | $18.67 |
| Resistance Level | $78.74 | $19.15 |
| Average True Range (ATR) | 2.21 | 0.31 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 70.32 | 35.29 |
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.